OGN Jan 2025 7.500 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.0500

0.0000

(0.00%)

As of 10:05AM EDT. Market open.

Loading interactive chart…

Business Wire
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
SHANGHAI, China & JERSEY CITY, N.J., September 30, 2024--Henlius and Organon announce primary endpoint met in phase 3 comparative clinical study of Perjeta® (pertuzumab) biosimilar candidate HLX11
Zacks
Are Options Traders Betting on a Big Move in Organon (OGN) Stock?
Investors need to pay close attention to Organon (OGN) stock based on the movements in the options market lately.
Business Wire
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
JERSEY CITY, N.J., September 18, 2024--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.